These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29878051)

  • 21. Progress in measles and rubella elimination in Iran.
    Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of a rapid digital microfluidics-powered immunoassay for assessing measles and rubella infection and immunity in outbreak settings in the Democratic Republic of the Congo.
    Knipes AK; Summers A; Sklavounos AA; Lamanna J; de Campos RPS; Narahari T; Dixon C; Fobel R; Ndjakani YD; Lubula L; Magazani A; Muyembe JJ; Lay Y; Pukuta E; Waku-Kouomou D; Hao L; Kayembe JK; Fobel C; Dahmer J; Lee A; Ho M; Valenzuela JGC; Rackus DG; Shih R; Seale B; Chang A; Paluku G; Rota PA; Wheeler AR; Scobie HM
    PLoS One; 2022; 17(12):e0278749. PubMed ID: 36542608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination.
    Mahamud A; Masunu-Faleafaga Y; Walls L; Williams N; Garcia P; Teshale E; Williams R; Dulski T; Bellini WJ; Kutty PK
    Vaccine; 2013 Aug; 31(36):3683-7. PubMed ID: 23770334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.
    Murhekar MV; Gupta N; Hasan AZ; Kumar MS; Kumar VS; Prosperi C; Sapkal GN; Thangaraj JWV; Kaduskar O; Bhatt V; Deshpande GR; Thankappan UP; Bansal AK; Chauhan SL; Grover GS; Jain AK; Kulkarni RN; Sharma SK; Chaaithanya IK; Kharwal S; Mishra SK; Salvi NR; Sharma S; Sarmah NP; Sabarinathan R; Duraiswamy A; Rani DS; Kanagasabai K; Lachyan A; Gawali P; Kapoor M; Shrivastava AK; Chonker SK; Tilekar B; Tandale BV; Ahmad M; Sangal L; Winter A; Mehendale SM; Moss WJ; Hayford K
    Lancet Glob Health; 2022 Nov; 10(11):e1655-e1664. PubMed ID: 36240831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post mass-immunization measles outbreak in Taoyuan County, Taiwan: dynamics of transmission, vaccine effectiveness, and herd immunity.
    Lee MS; Lee LL; Chen HY; Wu YC; Horng CB
    Int J Infect Dis; 1998-1999 Winter; 3(2):64-9. PubMed ID: 10225982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies against measles and rubella virus among different age groups in Thailand: A population-based serological survey.
    Wanlapakorn N; Wasitthankasem R; Vichaiwattana P; Auphimai C; Yoocharoen P; Vongpunsawad S; Poovorawan Y
    PLoS One; 2019; 14(11):e0225606. PubMed ID: 31770412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using Locally Derived Seroprevalence Data on Measles, Mumps, Rubella, and Varicella by Birth Cohort to Determine Risks for Vaccine-Preventable Diseases During International Travel.
    Rosario-Rosario G; Gareca M; Kincaid H; Knouse MC
    J Travel Med; 2015; 22(6):396-402. PubMed ID: 26412393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.
    Plans P; de Ory F; Campins M; Álvarez E; Payà T; Guisasola E; Compte C; Vellbé K; Sánchez C; Lozano MJ; Aran I; Bonmatí A; Carreras R; Jané M; Cabero L
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1161-71. PubMed ID: 25666082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of population-based measles-rubella immunoglobulin G antibody prevalence between 2014 and 2019 in Lao People's Democratic Republic: Impacts of the national immunization program.
    Miyano S; Vynnycky E; Pattamavone C; Ichimura Y; Mori Y; Nouanthong P; Phounphenghack K; Tengbriacheu C; Khamphaphongphane B; Franzel L; Yang TU; Raaijimarkers H; Komada K; Ota T; Funato M; Takeda M; Hachiya M
    Int J Infect Dis; 2023 Apr; 129():70-77. PubMed ID: 36758852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vaccination coverage against measles and sero-epidemiology of measles-specific IgG antibodies in German children and adolescents].
    Poethko-Müller C; Mankertz A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1243-52. PubMed ID: 23990086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained measles elimination in Australia and priorities for long term maintenance.
    Gidding HF; Wood J; MacIntyre CR; Kelly H; Lambert SB; Gilbert GL; McIntyre PB
    Vaccine; 2007 May; 25(18):3574-80. PubMed ID: 17300858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measles and rubella seroprevalence among adults in Georgia in 2015: helping guide the elimination efforts.
    Khetsuriani N; Chitadze N; Russell S; Ben Mamou M
    Epidemiol Infect; 2019 Dec; 147():e319. PubMed ID: 31822310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.
    Johnson H; Hillary IB; McQuoid G; Gilmer BA
    Vaccine; 1995 Apr; 13(6):533-7. PubMed ID: 7483773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identify the susceptibility profile to measles in the general population: Serological survey of measles antibodies in Shaanxi province, China, in 2016.
    Pei L; Yang Y; Zhao X; Zhang S; Yuan L; Liu Y; Yu Y
    Vaccine; 2017 Dec; 35(52):7250-7255. PubMed ID: 29153585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits and Challenges in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination.
    Winter AK; Martinez ME; Cutts FT; Moss WJ; Ferrari MJ; McKee A; Lessler J; Hayford K; Wallinga J; Metcalf CJE
    J Infect Dis; 2018 Jul; 218(3):355-364. PubMed ID: 29562334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does rubella immunity predict measles immunity? A serosurvey of pregnant women.
    Kennedy CM; Burns BA; Ault KA
    Infect Dis Obstet Gynecol; 2006; 2006():13890. PubMed ID: 17485795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rubella control in Papua New Guinea: age-specific immunity informs strategies for introduction of rubella vaccine.
    Riddell M; Senn N; Clements CJ; Hobday L; Cowie B; Kurubi J; Kevin A; Siba P; Reeder JC; Morgan C
    Vaccine; 2012 Dec; 30(52):7506-12. PubMed ID: 23103194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology of measles, mumps and rubella in Italy.
    Gabutti G; Rota MC; Salmaso S; Bruzzone BM; Bella A; Crovari P;
    Epidemiol Infect; 2002 Dec; 129(3):543-50. PubMed ID: 12558337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measles seroprevalence after reactive vaccination campaigns during the 2015 measles outbreak in four health zones of the former Katanga Province, Democratic Republic of Congo.
    Keating P; Carrion Martin AI; Blake A; Lechevalier P; Uzzeni F; Gignoux E; Okonta C; Langendorf C; Smit S; Ahuka S; Suchard M; Pukuta E; Degail MA; Hansen L; Kibanza-Kyungu J; Ciglenecki I; Cohuet S
    BMC Public Health; 2019 Aug; 19(1):1153. PubMed ID: 31438898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.